First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced the publication of two patent applications for its enhanced enteric microgranule delivery formulation of adrulipase. The patents cover composition of matter and methods of use claims and were published by both the United States Patent and Trademark Office (USPTO) and the..
Immutep (Formerly known as Prima Biomed) Limited has successfully completed an A$80 million capital raise to support its clinical development pipeline. The company, a clinical-stage biotechnology firm specializing in LAG-3 immunotherapies for cancer and autoimmune diseases, believes that the new funding will fully support its current and expanded clinical program until Q1 CY2026. With a pro-form..
Orchard Therapeutics has raised $34 million in new capital from the second closing of a securities purchase agreement, extending its cash runway through to mid-2025. The funding will support the advancement of its hematopoietic stem cell (HSC) gene therapy portfolio and preparations for the US launch of OTL-200 for MLD, pending FDA approval. The company expects that this funding will provide imp..
TransCode Therapeutics has announced new data supporting the use of TTX-MC138 for the treatment of metastatic breast cancer. The RNA oncology company's lead therapeutic candidate, TTX-MC138, is designed to inhibit microRNA-10b, described as the master regulator of cancer progression in a number of advanced solid tumors including breast cancer. In a preclinical model of pancreatic adenocarcinoma,..
NurExone Biologic Inc. has reported positive imaging results from an internal preclinical study of its investigational drug ExoPTEN, which demonstrated successful nerve regeneration following traumatic transection of the spinal cord in rats. The company's ExoPTEN drug caused 75% of rats to regain hind limb reflex, some motor function, and sensory control. Subsequently, advanced Diffusion Tensor ..
Experts suggest that expanding eligibility for amyotrophic lateral sclerosis (ALS) trials could benefit patients and drug development. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which is an understatement according to investigators. Expanding inclusion criteria would allow more patients to access experimental treatments and help drug develope..
